TetraLogic Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. Co. has two clinical-stage product candidates in development: birinapant and suberohydroxamic acid 4-methoxycarbonyl phenyl ester (SHAPE). SHAPE is Co.'s proprietary histone deacetylase inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases, which causes apoptosis, or cell-death, in damaged cells.
|
Free TLOG Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |